ClinicalTrials.gg
CompletedNCT07670858Updated Oct 29, 2026

Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC)

A Phase 1 interventional study of Intralesional FLD-103 in Nodular Basal Cell Carcinoma, sponsored by Feldan Therapeutics. Completed at 10 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Feldan Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Oct 2024, registered Jun 2026).
Updated Oct 29, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Carcinoma, Basal Cell with a site in Australia — 1 open to participants now, 2 under way, none of them phase 3. Carcinoma, Basal Cell · Australia.

Enrollment
13th of 17
32 · median 75
Started
2024
the only one that year
Phase 1
3 of 18
none open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Feldan Therapeutics

Among the 18 studies in Carcinoma, Basal Cell with a site in Australia, this one is the 13th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 1, and was the 18th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

1 of the 18 studies in Carcinoma, Basal Cell with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Basal Cell with a site in Australia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine safety, tolerability, pharmacokinetics, preliminary efficacy, and Maximum Tolerable Dose (MTD), of intralesional FLD-103 when administered to subjects with Basal Cell Carcinoma (BCC). The main questions it aims to answer are:

  • Is FLD-103 safe and well tolerated?
  • What is a safe dose of FLD-103 for future studies?
  • How much FLD-103 enters the bloodstream and how long does it take to be cleared from the body?
  • Does FLD-103 reduce the size of the tumor?

Participants will:

  • Receive either a Single Ascending Dose (SAD) of FLD-103 or Multiple Ascending Doses (MAD) of FLD-103 once weekly for four (4) weeks.
  • Visit the clinic a day after receiving a dose and once weekly for four (4) weeks after that for checkups and tests.
03

Conditions studied

  • Nodular Basal Cell Carcinoma

Browse trials for

Keywords

  • nBCC
  • Intralesional
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • You are between 18 and 85 years old.
  • You are willing to attend all study visits and follow the study procedures.
  • You have been diagnosed with at least one nodular basal cell carcinoma (a type of skin cancer) that has never been treated and suitable for treatment and final excision by the Investigator.
  • You are willing to avoid certain medications during the study as instructed by the study doctor.
  • You are not currently participating in another clinical study.
  • If you are a woman who could become pregnant, you must:
  • Have a negative pregnancy test at the start of the study.
  • Use effective during the study and for 90 days after your last dose.
  • Not breastfeed during the study and for 90 days after your last dose.
  • If you are a man, you must use a condom during the study and for 90 days after your last dose if you have sex with a partner who could become pregnant.

Exclusion criteria

Exclusion Criteria:

  • You are currently breastfeeding.
  • You have a known allergy or sensitivity to any ingredient in the study drug or to red tattoo ink.
  • Your skin lesion is located in a high-risk area, such as near the eyes, nose, ears, lips, scalp, or on the hands or fingers.
  • Your skin lesion needs to be removed urgently.
  • Your basal cell carcinoma has spread to other parts of the body.
  • You have received radiation therapy directly on or near the skin lesion being treated in this study.
  • You have received phototherapy (such as Ultraviolet A or B light therapy) in the past 4 weeks or are expected to receive it during the study.
  • You have been diagnosed with a liver or kidney disease that the study doctor considers significant.
  • You are or have an active infection such as (HIV), , or active Tuberculosis.
  • You have or had another cancer in the past 5 years
  • You have a skin condition associated with an increased risk of developing skin cancers (such as Xeroderma Pigmentosum).
  • You have uncontrolled high blood pressure or a heart rhythm problem.
  • You have had significant alcohol or drug use issues in the past 6 months, or have a mental health condition that the study doctor believes may affect your ability to participate safely.
  • You are currently taking certain medications that are not allowed during the study
  • You are an employee or family member of an employee at the study site or of the study doctor.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    SAD Dose 1

    A single dose of FLD-103 0.5 mg/mL (lesion size-determined volume)

    Drug: Intralesional FLD-103

  • Experimental
    SAD Dose 2

    A single dose of FLD-103 1 mg/mL (lesion size-determined volume)

    Drug: Intralesional FLD-103

  • Experimental
    SAD Dose 3

    A single dose of FLD-103 3 mg/mL (lesion size-determined volume)

    Drug: Intralesional FLD-103

  • Experimental
    SAD Dose 4

    A single dose of FLD-103 5 mg/mL (lesion size-determined volume)

    Drug: Intralesional FLD-103

  • Experimental
    MAD Dose 1

    A multiple doses of FLD-103 0.5 mg/mL once weekly for four (4) weeks (lesion size-determined volume).

    Drug: Intralesional FLD-103

  • Experimental
    MAD Dose 2

    A multiple doses of FLD-103 1 mg/mL once weekly for four (4) weeks (lesion size-determined volume).

    Drug: Intralesional FLD-103

  • Experimental
    MAD Dose 3

    A multiple doses of FLD-103 3 mg/mL once weekly for four (4) weeks (lesion size-determined volume).

    Drug: Intralesional FLD-103

  • Experimental
    MAD Dose 4

    A multiple doses of FLD-103 5 mg/mL once weekly for four (4) weeks (lesion size-determined volume).

    Drug: Intralesional FLD-103

  • Experimental
    MAD-FV Dose 2

    A multiple doses of FLD-103 1 mg/mL once weekly for four (4) weeks with a fixed volume (FV).

    Drug: Intralesional FLD-103

Interventions

  • DrugIntralesional FLD-103

    Intralesional and perilesional injection of FLD-103

06

What researchers measure

Primary outcomes

  1. Frequency, severity and relationship of Treatment Emergent Adverse events (TEAEs)

    Time frame: From enrollment until the end-of-study (EOS) visit (up to Day 36 for SAD / up to Day 57 for MAD/MAD-FV)

  2. Local Skin Response (LSR) and other potential localised responses

    Time frame: From enrollment until the end-of-study (EOS) visit (up to Day 36 for SAD / up to Day 57 for MAD/MAD-FV)

Secondary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: From enrollment until the end of treatment (EOT) (up to Day 8 for SAD / up to Day 36 for MAD/MAD-FV)

  2. Time to Cmax (Tmax)

    Time frame: From enrollment until the end of treatment (EOT) (up to Day 8 for SAD / up to Day 36 for MAD/MAD-FV)

  3. Area under the concentration-time curve from 0 to time of last quantifiable concentration (AUClast)

    Time frame: From enrollment until the end of treatment (EOT) (up to Day 8 for SAD / up to Day 36 for MAD/MAD-FV)

Other outcomes

  1. Rate of histological clearance of the nBCC

    Time frame: End-of-study (EOS) visit (up to Day 36 for SAD / up to Day 57 for MAD/MAD-FV)

  2. Overall response rate (ORR)

    Time frame: End-of-study (EOS) visit (up to Day 36 for SAD / up to Day 57 for MAD/MAD-FV)

  3. Complete response rate (CRR)

    Time frame: End-of-study (EOS) visit (up to Day 36 for SAD / up to Day 57 for MAD/MAD-FV)

07

Study locations

10 sites
  • Equity Medical
    Bowling Green, Kentucky 42104, United States
  • Equity Medical
    Owensboro, Kentucky 42303, United States
  • Equity Medical
    New York, New York 10023, United States
  • Woden Dermatology
    Phillip, Australian Capital Territory 2606, Australia
  • Novatrials
    Charlestown, New South Wales 2290, Australia
  • Scientia Clinical Research
    Randwick, New South Wales 2031, Australia
  • Innovate Clinical Research
    Waitara, New South Wales 2077, Australia
  • Veracity Clinical Research
    Greenslopes, Queensland 4120, Australia
  • FNQH Cairns Skin Cancer Clinic
    Westcourt, Queensland 4870, Australia
  • Translational Research Institute
    Woolloongabba, Queensland 4102, Australia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Oct 2026, 23 months.

Of 28 phase 1 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 51. This study's 23 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Feb 2027 → Oct 2026 and completion Mar 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jun 26, 2026
StartActual
Oct 30, 2024
Primary completionActual
Oct 26, 2026was Feb 2027
CompletionActual
Oct 26, 2026was Mar 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 29, 2026
Sites
2 sites added, 1 site removed
Show 2 added (1 United States, 1 Australia)
  • Equity Medical · Owensboro, United States
  • Veracity Clinical Research · Greenslopes, Australia
Show 1 removed
  • Veracity Clinical Research · Woolloongabba, Australia
Oct 29, 2026
Primary completion
Feb 2027→Oct 26, 2026 (actual)
Oct 29, 2026
Study completion
Mar 2027→Oct 26, 2026 (actual)
Oct 29, 2026
Enrollment
48 (estimated)→32 (actual)
Oct 29, 2026
Interventions
Arms removed: MAD-FV Dose 3·MAD-FV Dose 4
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Completed
    2 sites added, 1 site removed
    Show 2 added (1 United States, 1 Australia)
    • Equity Medical · Owensboro, United States
    • Veracity Clinical Research · Greenslopes, Australia
    Show 1 removed
    • Veracity Clinical Research · Woolloongabba, Australia
    Primary completion Feb 2027→Oct 26, 2026 (now actual)
    Study completion Mar 2027→Oct 26, 2026 (now actual)
    Enrollment 48 (estimated)→32 (actual)
    Interventions Arms removed: MAD-FV Dose 3·MAD-FV Dose 4
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07670858
Lead sponsor
Feldan Therapeutics
Responsible party
Sponsor
First posted
Jun 26, 2026
Start date
Oct 30, 2024
Primary completion
Oct 26, 2026
Completion
Oct 26, 2026
Last update
Oct 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion